NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
0.9300
-0.1000 (-9.71%)
At close: Nov 7, 2025, 4:00 PM EST
0.9700
+0.0400 (4.30%)
After-hours: Nov 7, 2025, 7:04 PM EST
NeuroSense Therapeutics Market Cap
NeuroSense Therapeutics has a market cap or net worth of $23.29 million as of November 7, 2025. Its market cap has increased by 4.01% in one year.
Market Cap
23.29M
Enterprise Value
22.62M
1-Year Change
4.01%
Ranking
Category
Stock Price
$0.93
Market Cap Chart
Since the IPO on December 9, 2021, NeuroSense Therapeutics's market cap has decreased from $64.61M to $23.29M, a decrease of -63.95%. That is a compound annual growth rate of -22.94%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Nov 7, 2025 | 23.29M | -16.07% |
| Dec 31, 2024 | 27.75M | 158.68% |
| Dec 29, 2023 | 10.73M | -24.68% |
| Dec 30, 2022 | 14.24M | -46.24% |
| Dec 31, 2021 | 26.49M | -59.00% |
| Dec 9, 2021 | 64.61M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 852.66B |
| Johnson & Johnson | 449.36B |
| AbbVie | 380.59B |
| UnitedHealth Group | 296.66B |
| AstraZeneca | 253.45B |
| Novartis AG | 240.68B |
| Abbott Laboratories | 216.19B |
| Novo Nordisk | 215.64B |